Nivolumab is a monoclonal antibody binds to the PD-1 receptor on T-cells, blocking cancer cells from turning off the immune response. Nivolumab has anti-tumor activity and can be used for melanoma, non-small cell lung cancer, renal cell carcinoma research.

PD-1 (activated T cells):0.64 nM (EC50), PD1-PDL1:2.52 nM, interaction between PD-1 and PD-L2:2.59 nM, PD-1 (CHO cells):1.66 nM (EC50)

METHODS: CD4+ T cells were co-cultured with DC cells for 6 days, treated with Nivolumab (0-1000 nmol/L), and the supernatant was collected on day 5 to measure IFNγ production by ELISA.
RESULTS: In allogeneic MLR, blockade of PD-1 with Nivolumab systematically resulted in titratable enhancement of IFNγ release. [1]
METHODS: Human colon cancer cells HT29, HCT116 and LoVo were treated with Nivolumab (1 µM) and different chemotherapeutic regimens for 72 h. Cell viability was measured by SRB assay.
RESULTS: Nivolumab decreased the efficacy of chemotherapy and increased the IC50 of 5-FU (3.1-fold, 2.2-fold, and 1.9-fold), OXA (2.8-fold, 4.8-fold, and 15.8-fold), and IRI (2.2-fold, 1.7-fold, and 2.9-fold) in HT29, HCT116, and LoVo, respectively. Nivolumab increased the IC50 for CDDP, DOXO, and TAX.[2]

Method: To assay antitumor activity in vivo, Nivolumab (200 µg) was injected intraperitoneally into huNOG or huNOG FcγR-/- mice harboring HSC4, RKO, HCC827, or NCI-H1975 tumors once a week for four weeks.
Result: In huNOG mice, Nivolumab did not inhibit any xenogeneic human tumors, whereas the growth of HSC4, HCC827, and NCI-H1975 (but not RKO) tumors in huNOG FcγR-/- mice was strongly inhibited or even rejected after Nivolumab treatment. In some experiments, tumor growth was enhanced in Nivolumab-treated huNOG mice, such as HCC827.^[3]
Method: GL261 bearing mice model received nivolumab treatment at a dose of 5 mg/kg by intravenous injection twice per week for a total of six treatments (on days 1, 4, 7, 10, 13, and 16). Tumor progression was monitored using MRI scans.
Resluts: Nivolumab GL261 inhibited tumor growth compared to the control group in GL261 bearing mice model and does not induce tissue damage, biochemical changes, or changes in the body weight of mice.^[4]

Human

Immobilized Human PD-1 Protein (His) (TMPY-00897) at 1 μg/mL (100 μL/well) can bind Nivolumab. The EC50 is 0.470 ng/mL.

Monoclonal

Unconjugated